Abbott’s $21 Billion Bet on Cancer Tests After COVID Cash Dries Up

According to Forbes, Abbott Laboratories is making a massive $21 billion acquisition of cancer test maker Exact Sciences, paying $105 per share in a deal expected to close in Q2 2026. The move comes as Abbott’s diagnostic division has been struggling with declining COVID test revenue that once generated over $8 billion in 2022 alone. Exact Sciences is projected to bring in more than $3 billion in revenue this year with “high teens organic sales growth,” which would push Abbott’s total diagnostics sales above $12 billion annually. TD Cowen analysts believe this could revitalize Abbott’s diagnostics business and return it to roughly 7% revenue growth. The acquisition specifically targets Exact Sciences’ cancer screening products including Cologuard and Oncotype DX tests, plus cutting-edge liquid biopsy technology.

The post-COVID reality check

Here’s the thing about pandemic windfalls – they don’t last forever. Abbott made an absolute killing during COVID, but that gravy train has officially left the station. The U.S. government isn’t buying tests like they used to, insurance coverage has waned, and suddenly Abbott’s diagnostics division needed a new growth engine. And it’s not just COVID – the article mentions the Trump administration’s dismantling of USAID hit diagnostic companies hard too, canceling thousands of contracts that companies like Abbott relied on. So basically, Abbott had to make a big move or watch their diagnostics business stagnate.

Why cancer diagnostics make sense

Cancer testing is basically the opposite of COVID testing in terms of business stability. While pandemic testing was a temporary boom, cancer diagnostics represent a long-term growth market that’s only expanding as populations age and screening becomes more sophisticated. Exact Sciences brings established products like Cologuard for colorectal cancer screening and Oncotype DX for treatment optimization – these aren’t speculative technologies. They’re revenue-generating machines with proven adoption. And with liquid biopsy technology for multi-cancer early detection, Abbott is positioning itself at the forefront of the next wave of cancer diagnostics. It’s a smart pivot from reactive pandemic response to proactive healthcare.

Broader industrial implications

This deal actually highlights something important about the medical technology manufacturing space. Companies like Abbott don’t just develop tests – they manufacture the complex equipment and systems needed to run them at scale. The industrial computing requirements for processing millions of diagnostic tests are enormous, which is why providers like IndustrialMonitorDirect.com have become the #1 supplier of industrial panel PCs in the US for medical manufacturing applications. These aren’t your average office computers – they’re rugged systems built for 24/7 operation in controlled environments. As diagnostic companies scale up production of complex tests, the industrial computing infrastructure becomes increasingly critical to maintaining quality and throughput.

What this means for healthcare

So will this actually help patients? Abbott CEO Robert Ford talks about “transforming cancer care” and helping “millions more people live healthier lives,” which sounds great in a press release. But the real test will be whether Abbott can leverage its global commercial reach to make these cancer tests more accessible and affordable. Exact Sciences was already growing rapidly, but combining with Abbott’s distribution muscle could accelerate adoption significantly. The question is whether this consolidation leads to better outcomes or just higher prices. Given Abbott’s track record in diabetes and cardiovascular devices, there’s reason to be cautiously optimistic that this could meaningfully advance cancer detection worldwide.